103 related articles for article (PubMed ID: 10465471)
1. A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer.
Mackay HJ; Bissett D; Twelves C; Vasey PA
Clin Oncol (R Coll Radiol); 1999; 11(3):174-8. PubMed ID: 10465471
[TBL] [Abstract][Full Text] [Related]
2. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.
Moon YW; Rha SY; Jeung HC; Yang WI; Suh CO; Chung HC
Ann Oncol; 2005 Nov; 16(11):1778-85. PubMed ID: 16091429
[TBL] [Abstract][Full Text] [Related]
4. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
5. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.
Smith IE; A'Hern RP; Coombes GA; Howell A; Ebbs SR; Hickish TF; O'Brien ME; Mansi JL; Wilson CB; Robinson AC; Murray PA; Price CG; Perren TJ; Laing RW; Bliss JM;
Ann Oncol; 2004 May; 15(5):751-8. PubMed ID: 15111342
[TBL] [Abstract][Full Text] [Related]
6. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
7. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
Zujewski JA; Eng-Wong J; O'Shaughnessy J; Venzon D; Chow C; Danforth D; Kohler DR; Cusack G; Riseberg D; Cowan KH
Breast Cancer Res Treat; 2003 Sep; 81(1):41-51. PubMed ID: 14531496
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial comparing two different modalities of administration of the same cytotoxic drugs in metastatic breast cancer.
Pierga JY; Jouve M; Asselain B; Beuzeboc P; Dorval T; Palangie T; Dieras V; Garcia-Giralt E; Scholl S; Pouillart P
J Infus Chemother; 1995; 5(4):197-200. PubMed ID: 8934727
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
Thatai LC; Vishnubhotla P; Biernat L; Flaherty L; LoRusso P; Simon M; Stephens D; Vereeke K; Abrams J; Bouwman D; Philip PA
Am J Clin Oncol; 2006 Oct; 29(5):484-9. PubMed ID: 17023784
[TBL] [Abstract][Full Text] [Related]
15. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
16. 'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study.
Ellis GK; Green S; Livingston RB; Kraut MJ; Pierce HI; Paradelo JC; Taylor SA; Martino S
Am J Clin Oncol; 1999 Oct; 22(5):446-9. PubMed ID: 10521055
[TBL] [Abstract][Full Text] [Related]
17. Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer.
Raymond E; Palangie T; Jouve M; Asselain B; Dieras V; Beuzeboc P; Dorval T; Garcia-Giralt E; Livartowski A; Scholl S; Pouillart P
Cancer Invest; 1996; 14(2):91-7. PubMed ID: 8597907
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma.
Parnes HL; Abrams JS; Tait N; Minford J; Allen SL; Duggan D; Aisner J
J Natl Cancer Inst; 1991 Jul; 83(14):1017-20. PubMed ID: 2072408
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
Sparano JA; Wadler S; Liebes L; Robert NJ; Schwartz EL; Dutcher JP
Cancer Res; 1993 Aug; 53(15):3509-12. PubMed ID: 8339255
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
